Aβ42 and ROS dual-targeted multifunctional nanocomposite for combination therapy of Alzheimer's disease

Liding Zhang,Kai Cao,Jun Xie,Xiaohan Liang,Hui Gong,Qingming Luo,Haiming Luo

DOI: https://doi.org/10.1186/s12951-024-02543-z

IF: 10.2

2024-05-24

Journal of Nanobiotechnology

Abstract:Amyloid-β (Aβ) readily misfolds into neurotoxic aggregates, generating high levels of reactive oxygen species (ROS), leading to progressive oxidative damage and ultimately cell death. Therefore, simultaneous inhibition of Aβ aggregation and scavenging of ROS may be a promising therapeutic strategy to alleviate Alzheimer's disease pathology. Based on the previously developed antibody 1F12 that targets all forms of Aβ 42 , we developed an Aβ 42 and ROS dual-targeting nanocomposite using biodegradable mesoporous silica nanoparticles as carriers to load ultra-small cerium oxide nanocrystals (bMSNs@Ce-1F12). By modifying the brain-targeted rabies virus glycoprotein 29 (RVG29-bMSNs@Ce-1F12), this intelligent nanocomposite can efficiently target brain Aβ-rich regions. Combined with peripheral and central nervous system treatments, RVG29-bMSNs@Ce-1F12 can significantly alleviate AD symptoms by inhibiting Aβ 42 misfolding, accelerating Aβ 42 clearance, and scavenging ROS. Furthermore, this synergistic effect of ROS scavenging and Aβ clearance exhibited by this Aβ 42 and ROS dual-targeted strategy also reduced the burden of hyperphosphorylated tau, alleviated glial cell activation, and ultimately improved cognitive function in APP/PS1 mice. Our findings indicate that RVG29-bMSNs@Ce-1F12 is a promising nanodrug that can facilitate multi-target treatment of AD.

biotechnology & applied microbiology,nanoscience & nanotechnology

What problem does this paper attempt to address?

The paper attempts to address the issues of β-amyloid protein (Aβ42) aggregation and excessive reactive oxygen species (ROS) generation in Alzheimer's disease (AD). Specifically, the paper proposes an innovative therapeutic approach by developing a multifunctional nanocomposite (RVG29-bMSNs@Ce-1F12) that can simultaneously inhibit Aβ42 aggregation, accelerate Aβ42 clearance, and effectively eliminate ROS, thereby alleviating the pathological features of AD. This approach aims to reduce neuronal damage caused by Aβ42 and ROS through a multi-target therapeutic strategy, thereby improving the cognitive function of AD patients.

Key points of the paper include:
1. **The relationship between Aβ42 aggregation and ROS generation**: Aβ42 aggregation leads to high concentrations of ROS, which in turn causes oxidative stress and ultimately cell death. Therefore, simultaneously inhibiting Aβ42 aggregation and eliminating ROS may be an effective therapeutic strategy.
2. **Design of the multifunctional nanocomposite**: Researchers designed a nanocomposite based on biodegradable mesoporous silica nanoparticles (bMSNs), loaded with ultra-small cerium oxide nanocrystals (CeNPs), and surface-modified with brain-targeting peptide RVG29 and anti-Aβ42 antibody 1F12.
3. **Experimental validation**: Through in vitro and in vivo experiments, the effectiveness of RVG29-bMSNs@Ce-1F12 in inhibiting Aβ42 aggregation, accelerating Aβ42 clearance, and eliminating ROS was validated. The results showed that this nanocomposite could significantly improve the cognitive function of AD model mice, reduce the levels of Aβ42 and ROS, and alleviate tau protein hyperphosphorylation and glial cell activation.

In summary, the paper proposes an innovative multi-target therapeutic strategy aimed at addressing the key pathological mechanisms in AD through nanotechnology, providing new ideas and methods for the treatment of AD.